GeneDx - Pompe disease is a glycogen storage disease affecting 1 in every 13,000 people. Pompe Support Network explains that despite diagnostic genetic test availability, adults suffer with increasing muscle weakness &
1,6-epi-Cyclophellitol Cyclosulfamidate Is a Bona Fide Lysosomal α-Glucosidase Stabilizer for the Treatment of Pompe Disease | Journal of the American Chemical Society
![Muscle‐directed gene therapy corrects Pompe disease and uncovers species‐specific GAA immunogenicity | EMBO Molecular Medicine Muscle‐directed gene therapy corrects Pompe disease and uncovers species‐specific GAA immunogenicity | EMBO Molecular Medicine](https://www.embopress.org/cms/asset/a2942442-98b3-4a59-963b-97985b17a85d/emmm202113968-abs-0001-m.jpg)
Muscle‐directed gene therapy corrects Pompe disease and uncovers species‐specific GAA immunogenicity | EMBO Molecular Medicine
![Biomolecules | Free Full-Text | Pompe Disease: New Developments in an Old Lysosomal Storage Disorder Biomolecules | Free Full-Text | Pompe Disease: New Developments in an Old Lysosomal Storage Disorder](https://www.mdpi.com/biomolecules/biomolecules-10-01339/article_deploy/html/images/biomolecules-10-01339-g001.png)
Biomolecules | Free Full-Text | Pompe Disease: New Developments in an Old Lysosomal Storage Disorder
![Correction of oxidative stress enhances enzyme replacement therapy in Pompe disease | EMBO Molecular Medicine Correction of oxidative stress enhances enzyme replacement therapy in Pompe disease | EMBO Molecular Medicine](https://www.embopress.org/cms/asset/b36ef59a-f869-41a9-95ba-5962a21021e4/emmm202114434-abs-0001-m.jpg)
Correction of oxidative stress enhances enzyme replacement therapy in Pompe disease | EMBO Molecular Medicine
![Facial-muscle weakness, speech disorders and dysphagia are common in patients with classic infantile Pompe disease treated with enzyme therapy | SpringerLink Facial-muscle weakness, speech disorders and dysphagia are common in patients with classic infantile Pompe disease treated with enzyme therapy | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs10545-011-9404-7/MediaObjects/10545_2011_9404_Fig1_HTML.gif)
Facial-muscle weakness, speech disorders and dysphagia are common in patients with classic infantile Pompe disease treated with enzyme therapy | SpringerLink
![Orofacial features and pediatric dentistry in the long-term management of Infantile Pompe Disease children | Orphanet Journal of Rare Diseases | Full Text Orofacial features and pediatric dentistry in the long-term management of Infantile Pompe Disease children | Orphanet Journal of Rare Diseases | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13023-020-01615-1/MediaObjects/13023_2020_1615_Fig1_HTML.jpg)
Orofacial features and pediatric dentistry in the long-term management of Infantile Pompe Disease children | Orphanet Journal of Rare Diseases | Full Text
![Pathophysiology of late-onset Pompe disease. Abbreviations: GAA, acid... | Download Scientific Diagram Pathophysiology of late-onset Pompe disease. Abbreviations: GAA, acid... | Download Scientific Diagram](https://www.researchgate.net/publication/283830410/figure/fig3/AS:296548907929604@1447714177311/Pathophysiology-of-late-onset-Pompe-disease-Abbreviations-GAA-acid-alpha-glucosidase.png)
Pathophysiology of late-onset Pompe disease. Abbreviations: GAA, acid... | Download Scientific Diagram
![Enzyme Replacement Therapy Can Reverse Pathogenic Cascade in Pompe Disease: Molecular Therapy - Methods & Clinical Development Enzyme Replacement Therapy Can Reverse Pathogenic Cascade in Pompe Disease: Molecular Therapy - Methods & Clinical Development](https://www.cell.com/cms/attachment/d477ae79-5c78-483c-8573-a695c6239c25/fx1_lrg.jpg)